Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes (redOrbit)

Posted by admin
June 6, 2009
NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today new, positive Phase II study results of LY2189265, its investigational glucagon-like peptide 1 (GLP-1) analog administered subcutaneously once-weekly for the treatment of type 2 diabetes.
Chiropractor, Back Pain, Sore Neck

If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.

Comments

No comments yet.

Sorry, the comment form is closed at this time.